Evaluation of the substrate envelope hypothesis for inhibitors of HIV‐1 protease
- 1 May 2007
- journal article
- research article
- Published by Wiley in Proteins: Structure, Function, and Bioinformatics
- Vol. 68 (2) , 561-567
Abstract
Crystallographic data show that various substrates of HIV protease occupy a remarkably uniform region within the binding site; this region has been termed the substrate envelope. It has been suggested that an inhibitor that fits within the substrate envelope should tend to evade viral resistance because a protease mutation that reduces the affinity of the inhibitor will also tend to reduce the affinity of substrate, and will hence decrease the activity of the enzyme. Accordingly, inhibitors that fit the substrate envelope better should be less susceptible to clinically observed resistant mutations, since these must also allow substrates to bind. The present study describes a quantitative measure of the volume of a bound inhibitor falling outside the substrate envelope, and observes that this quantity correlates with the inhibitor's losses in affinity to clinically relevant mutants. This measure may thus be useful as a penalty function in the design of robust HIV protease inhibitors. Proteins 2007.Keywords
This publication has 21 references indexed in Scilit:
- Combating Susceptibility to Drug ResistanceLessons from HIV-1 ProteaseChemistry & Biology, 2004
- Multidrug Resistance to HIV-1 Protease Inhibition Requires Cooperative Coupling between Distal MutationsBiochemistry, 2003
- Viability of a Drug-Resistant Human Immunodeficiency Virus Type 1 Protease Variant: Structural Insights for Better Antiviral TherapyJournal of Virology, 2003
- A Major Role for a Set of Non-Active Site Mutations in the Development of HIV-1 Protease Drug ResistanceBiochemistry, 2003
- How does a symmetric dimer recognize an asymmetric substrate? a substrate complex of HIV-1 proteaseJournal of Molecular Biology, 2000
- The Protein Data BankNucleic Acids Research, 2000
- All-Atom Empirical Potential for Molecular Modeling and Dynamics Studies of ProteinsThe Journal of Physical Chemistry B, 1998
- Viracept (Nelfinavir Mesylate, AG1343): A Potent, Orally Bioavailable Inhibitor of HIV-1 ProteaseJournal of Medicinal Chemistry, 1997
- Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzymeJournal of the American Chemical Society, 1995
- Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostereJournal of Medicinal Chemistry, 1991